Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Relapsed/Refractory Triple-Negative Breast Cancer

NCT02161679 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02161679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02161679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Relapsed/Refractory Triple-Negative Breast Cancer
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Withdrawn
Start date
August 31, 2016
Completion date
August 31, 2016
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer